^
    11ms
    Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. (PubMed, Clin Lung Cancer)
    Neratinib had meaningful activity in selected patients with EGFR exon 18-mutant NSCLC, including patients pretreated with ≥1 TKI. Diarrhea was generally low grade. Given the lack of effective treatments after EGFR TKI failure for NSCLC with uncommon mutations, further examination of neratinib is warranted.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719A
    |
    Nerlynx (neratinib)
    1year
    A Case Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges. (PubMed, Cureus)
    The patient had two metachronous lung primary cancers resected in 2022 and 2024. Due to the complete surgical resection, the sensitivity of this mutation of TKIs could not be established. This unique mutation profile still remains of paramount importance to understand if the patient relapses or presents with a new tumor with the same genetic profile.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • PD-L1 negative • EGFR G719A
    |
    PD-L1 IHC 22C3 pharmDx
    1year
    A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells. (PubMed, Sci Rep)
    Studies have shown that afatinib is beneficial for NSCLC patients with rare EGFR mutations...The results showed that WZ3146 induced cytotoxic effects, inhibited growth vitality and proliferation via ERK and AKT pathway in the EGFR G719X mutant cells. Our findings suggest that WZ3146 may be a promising treatment option for NSCLC patients with the EGFR exon 18 substitution mutation G719X.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719X • EGFR G719A • EGFR G719S • EGFR exon 18 mutation • EGFR G719C
    |
    Gilotrif (afatinib)
    almost2years
    MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study. (PubMed, Clin Transl Oncol)
    MET positive expression was an independent predictor of poor outcomes in untreated EGFR L858R mutation advanced LUAD patients treated with first-line EGFR-TKI monotherapy.
    Retrospective data • Journal • Real-world evidence • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR expression • MET overexpression • EGFR L861Q • EGFR S768I • MET expression • MET positive • EGFR G719A • EGFR G719C
    2years
    Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. (PubMed, Cancer Med)
    The combination of sintilimab and anlotinib demonstrated durable efficacy and was generally well tolerated in patients with NSCLC and uncommon EGFR mutations who had received prior standard-of-care treatments. (ClinicalTrials.gov identifier: NCT04790409).
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719A
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    over2years
    Real-world data on next-generation sequencing using comprehensive genomic profiling assays for detecting driver oncogenes in advanced non-small cell lung cancer: Analysis with the National Database of Japan (ESMO 2023)
    The other driver oncogenes detected using CGP assays were 23 (7.0%) patients of KRAS G12C, 40 (12.1%) patients of KRAS non-G12C, 20 (6.1%) patients of HER2 mutation, 14 (4.2%) patients of MET exon 14 skipping, and 4 (1.2%) patients of RET. Conclusions CGP assays are useful for identifying driver oncogenes in patients with advanced NSCLC, especially for patients whose driver oncogenes were not identified at initial diagnosis.
    Clinical • Real-world evidence • Next-generation sequencing • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation • MET mutation • KRAS G12 • EGFR G719A
    over2years
    Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd) (ESMO 2023)
    Updated results will be presented (data cutoff, December 2021). Table: 151P Efficacy according to mutation status
    Clinical • Circulating tumor DNA • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • NRAS mutation • EGFR L858R • HER-2 mutation • EGFR T790M • STK11 mutation • RAS mutation • KEAP1 mutation • EGFR S768I • EGFR G719A • EGFR E746
    |
    GuardantOMNI
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    over2years
    Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases (IASLC-WCLC 2023)
    Furmonertinib 160mg orally once daily has shown encouraging efficacy as first-line therapy in EGFR-mutated advanced NSCLC patients with CNS metastases. Patients were well tolerated and the AEs were consistent with previous studies.
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive • EGFR G719A
    |
    Ivesa (firmonertinib)
    over2years
    Evaluation of EGFR and GeneFusion Assay Using Biocartis Idylla Technology in Lung Adenocarcinoma (AMP Europe 2023)
    The Idylla EGFR testing is an accurate and simple tool useful for the early screening of EGFR mutations. The Idylla GeneFusion is a potential screening panel with short turnaround time using a minimal amount of tissue and might be considered as a relevant complementary testing to IHC in diagnostic molecular laboratories.
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • RET fusion • EGFR expression • MET exon 14 mutation • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR S768I • EGFR G719A • EGFR exon 18 mutation
    |
    cobas® EGFR Mutation Test v2 • Idylla™ GeneFusion Assay • Idylla™ EGFR Mutation Test
    over2years
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=51, Recruiting, Mayo Clinic | N=77 --> 51
    Enrollment change
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • EGFR C797S • EGFRvIII mutation • EGFR G719A • IDH wild-type
    |
    WSD0922